Soo, Ross A. http://orcid.org/0000-0002-3053-3997
Seto, Takashi
Gray, Jhanelle E.
Thiel, Ellen
Taylor, Aliki
Sawyer, William
Karimi, Parisa
Marchlewicz, Elizabeth
Brouillette, Matthew
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 28 July 2021
First Online: 12 September 2021
Declarations
:
: This work was supported by AstraZeneca, the manufacturer of osimertinib.
: R. A. Soo declares grants and personal fees from AstraZeneca and Boehringer Ingelheim; personal fees from Amgen, Bristol Myers Squibb, Lilly, Merck, Novartis, Pfizer, Puma Biotechnology, Roche, Taiho, Takeda, and Yuhan; T. Seto declares grants, personal fees, and honoraria from AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, MSD, Nippon Boehringer Ingelheim, Novartis Pharma, Pfizer Japan, and Takeda Pharmaceutical; personal fees and honoraria from Astellas Pharma, Bristol Myers Squibb, Kyowa Hakko Kirin, Ono Pharmaceutical, Taiho Pharmaceutical, Thermo Fisher Scientific; and grants from AbbVie, Bayer Yakuhin, Kissei Pharmaceutical, LOXO Oncology, and Merck Serono. T. Seto also reports employment for Precision Medicine Asia Co. Ltd.; J.E. Gray declares grants, personal fees and non-financial support from AstraZeneca and Genentech, personal fees and non-financial support from Takeda, grant and personal fees from Bristol Myers Squibb; grants from Boehringer Ingelheim, Array, Merck and personal fees from EMD Serono Merck; E. Thiel declares funding from AstraZeneca (AstraZeneca paid funds to IBM Watson Health to conduct this analysis), personal fees and employment from IBM Watson Health; A. Taylor declares employment and shares with AstraZeneca; W. Sawyer and P. Karimi declare employment for AstraZeneca; E. Marchlewicz declares AstraZeneca contracted IBM Watson Health to provide consulting and data analysis services for this study; M. Brouillette declares employment with IBM Watson Health.
: Data underlying the findings described in this article may be obtained in accordance with AstraZeneca’s data-sharing policy described at: ExternalRef removed.
: Not applicable.
: Takashi Seto, Jhanelle E. Gray, Ellen Thiel, Aliki Taylor, William Sawyer, Parisa Karimi, Elizabeth Marchlewicz and Matthew Brouillette all substantially contributed to the acquisition, analysis, or interpretation of data for the work. Takashi Seto, Jhanelle E. Gray, Ellen Thiel and Elizabeth Marchlewicz substantially contributed to the conception or design of the work as well as project administration. Ross Soo, Takashi Seto, Jhanelle E. Gray, Ellen Thiel, Aliki Taylor, William Sawyer, Parisa Karimi, Elizabeth Marchlewicz and Matthew Brouillette contributed to writing – review and editing as well as writing – original draft of this work. Ellen Thiel, Aliki Taylor, William Sawyer, Parisa Karimi, Elizabeth Marchlewicz and Matthew Brouillette and contributed to the formal analysis. Jhanelle E. Gray, Ellen Thiel and Elizabeth Marchlewicz contributed to the conceptualization and investigation of the work. Ellen Thiel and Elizabeth Marchlewicz contributed to the resources and data curation for the work. Takashi Seto, Jhanelle E. Gray, Ellen Thiel, Aliki Taylor, William Sawyer and Elizabeth Marchlewicz contributed to the methodology. Ross Soo, Jhanelle E. Gray, Ellen Thiel and Elizabeth Marchlewicz contributed to the supervision of the work. William Sawyer contributed to the validation of the work.
: The study was performed in accordance with ethical principles consistent with the Declaration of Helsinki, ICH GCPs, GPP and the applicable legislation on Non-Interventional Studies and/or Observational Studies. The Investigators performed the Observational Study in accordance with the regulations and guidelines governing medical practice and ethics in the country of the Observational Study and in accordance with currently acceptable techniques and know-how. This study did not require review and approval by ethics committees or informed consent. All IBM Watson Health MarketScan<sup>®</sup> Commercial and Medicare Database records are de-identified and fully compliant with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act (HIPAA) of 1996. Because this study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data, Institutional Review Board approval to conduct this study was not necessary.
: Not applicable.
: Not applicable.